POLICY • NEWS • MARKETS
AG POLICY & MARKETS DAILY
FRIDAY, JULY 31, 2026 | SPECIAL REPORT & ANALYSIS
EARNINGS ANALYSIS | CORTEVA EARNINGS CALL
Corteva Raises Outlook as October Separation Approaches
Seed strength and cost gains offset crop protection pricing pressure
Analysis · July 31, 2026
Corteva entered the final months before its planned corporate separation with stronger-than-expected earnings, improving margins and increased confidence in its full-year outlook. Management during an earnings call said demand for advanced seed genetics, rapid growth in technology licensing, adoption of newer crop protection products and more than $160 million in cost benefits drove the first-half improvement.
However, the company continues to confront weak crop protection pricing in Brazil, tight farmer credit, elevated fuel and fertilizer expenses and geopolitical and trade-related costs that will be concentrated in the second half.
Corteva remains on track to separate its businesses Oct. 1, creating Vylor as an independent seed and genetics company and leaving the crop protection operation under the Corteva name. The earnings call was led by Chief Executive Officer Charles “Chuck” Magro and Chief Financial Officer David Johnson, with future New Corteva CEO Luther “Luke” Kissam and Seed Business Unit Executive Vice President Judd O’Connor participating in the question-and-answer session.
First-Half Performance and Increased Guidance — Answered by Charles Magro and David Johnson
Corteva’s first-half results showed that earnings growth was not dependent on a major improvement in the broader agricultural economy. Net sales increased 4% to $11.3 billion, while organic sales rose 2%. Operating EBITDA increased 10% to $3.7 billion, and the operating EBITDA margin expanded to 32.8%. Operating earnings per share increased 14%.
For the second quarter alone, sales totaled $6.4 billion and operating EBITDA increased 4% to $2.3 billion. Johnson emphasized that Corteva’s seasonality makes the half-year results more useful than individual quarters when evaluating the business.
Management increased its full-year operating EBITDA forecast to between $4.1 billion and $4.3 billion. At the $4.2 billion midpoint, EBITDA would increase approximately 9% from 2025. Corteva also raised its operating earnings-per-share forecast to between $3.60 and $3.80, representing approximately 11% growth at the midpoint. The operating EBITDA margin is now projected at 22.5% to 23.5%.
The most important feature of the results is the composition of the earnings improvement. Price and product mix added nearly $100 million to first-half EBITDA, volume contributed roughly $40 million and cost performance provided more than $160 million. Favorable currency movements added approximately $85 million, while improved seed royalties contributed another $90 million.
That combination indicates Corteva is generating earnings through several channels rather than relying on a single favorable market development. Seed pricing remains constructive, newer crop protection products are gaining volume, and internal cost reductions are offsetting pressure on older products. The improvement in royalties is particularly significant because licensing income can generate growth without requiring Corteva to manufacture and distribute all of the associated seed products itself.
Seed Technology, Licensing and Farmer Spending — Answered by Charles Magro
Magro said farmers continue to pay premiums for products that can improve yields, productivity and returns, even as overall farm margins remain tight. Corteva reported organic seed growth in every region during the first half, supported by newer genetics, trait offerings and technology licensing.
Management characterized the agricultural demand environment as healthy but selective. Global food, feed and biofuel demand continues to expand, and crop prices were higher than a year earlier. Yet farmers remain cautious about discretionary purchases and are prioritizing products that can demonstrate an identifiable economic return.
That distinction is favorable for Corteva’s seed operation. Seed purchases are generally among the last inputs growers are willing to reduce because genetics directly influence yield potential. Corteva’s strategy is therefore focused on capturing a portion of the additional value created by new products rather than attempting to generate growth through across-the-board price increases.
Licensing is also developing much faster than Corteva originally expected. Magro said the seed licensing business is approximately three years ahead of the company’s initial plan. The advancement of licensing provides Corteva with another way to monetize its traits and germplasm through outside seed companies while broadening the acreage on which its technology is used.
North American Corn and Soybean Market Share — Answered by Charles Magro
Corteva believes it gained a modest amount of U.S. corn market share during the 2026 planting season. Magro cited gains in Pioneer but said the more notable improvement came from Brevant, Corteva’s retail-oriented seed brand, which secured a larger share of shelf space.
In soybeans, Pioneer gained share in portions of both the western and eastern Corn Belt. However, Corteva lost some business in the Delta, where the return of dicamba-tolerant systems created competitive challenges, particularly in cotton-producing areas. Management expects overall soybean share to finish approximately unchanged, while corn share should show a small increase.
The corn gains are strategically important because Corteva said it maintained its premium value-capture strategy rather than pursuing market share primarily through discounting. Brevant’s progress also suggests Corteva is strengthening its access to retail channels alongside the company’s established Pioneer agency network.
Brazil Corn Acres, Seed Orders and Conkesta — Answered by Charles Magro
With most Northern Hemisphere seed sales completed, Corteva’s second-half seed performance will depend heavily on Latin America and especially Brazil. Management is using a relatively cautious assumption that Brazil’s corn area will be approximately flat after several years of low-single-digit growth in safrinha acreage.
Corteva’s order book was running ahead of the broader market, giving management confidence that the company was well positioned even if producers delay purchases. Magro said Corteva’s product lineup and pricing position in Latin America remain strong.
Conkesta E3 remains a major growth product. Corteva expects the insect-resistant and herbicide-tolerant soybean platform to achieve high-single-digit to low-double-digit market penetration in 2027. Management said adoption remains on plan and expressed continued optimism regarding the technology’s performance.
The primary uncertainty is not Corteva’s competitive position but the timing of Brazilian growers’ decisions. High interest rates, restricted credit and increased fuel and fertilizer expenses are pressuring producer margins. As a result, farmers are ordering closer to planting rather than committing as early as they did in the prior season.
Management nevertheless described Corteva’s Brazil seed portfolio as the strongest it has offered for both the summer crop and safrinha. The company’s confidence therefore rests on capturing a larger portion of a potentially flat market rather than requiring another substantial expansion in planted acres.
Seed Price, Volume and Second-Half Sales — Answered by Judd O’Connor and David Johnson
O’Connor stressed that Corteva’s seed business is heavily weighted toward the first half of the calendar year. Only about 27% of annual seed revenue is expected during the second half, with most of that activity centered on Brazil and, to a lesser degree, South Africa.
Management expects second-half seed volume to be relatively flat because Brazil is unlikely to repeat the recent pace of safrinha acreage expansion. However, Corteva anticipates approximately equal contributions from price and volume to second-half organic seed growth. Johnson described the expected split as roughly 50-50, with slight gains in both categories.
The price component will be driven primarily by product mix rather than simple list-price increases. As Corteva introduces higher-value genetics and traits, the company expects to share in part of the incremental economic value delivered to producers.
Crop Protection Market and Pricing Pressure — Answered by Charles Magro and David Johnson
Crop Protection remains the principal area of pricing risk. Corteva reported low-single-digit price declines during the first half and expects prices to fall by the low- to mid-single digits during the second half. The greatest pressure is in Brazil, with additional weakness in a small number of other markets.
Magro said prices in the U.S. and Europe were essentially flat during the first half. Corteva’s newer crop protection products also maintained approximately flat prices while recording high-single-digit volume growth. The newer-product portfolio is expected to approach $2 billion in annual revenue during 2026.
The price erosion is concentrated in older products, including active ingredients that have lost patent protection and now face generic competition. Corteva anticipated that transition and reduced production costs before generic alternatives became more widely available. As a result, the company has been able to reduce prices while protecting margins and market share.
Management continues to view the overall crop protection market as gradually improving. Corteva expects the market to grow at a low-single-digit rate in 2026, with volume growth offsetting price declines. Chinese exports into Brazil and the U.S. were described as stable rather than increasing, reducing the risk of another major influx of low-cost inventory.
The earnings implications are more favorable than the headline price reductions suggest. Johnson said lower manufacturing costs and productivity programs should allow Crop Protection to increase EBITDA despite falling prices. The key measurement is therefore the margin and profit generated from each product, not the nominal selling price alone.
Brazil Crop Protection Outlook — Answered by Charles Magro
Magro rejected the idea that high-single-digit price declines represent a permanent condition in Brazil. The Brazilian market remains well supplied, but underlying demand is supported by expanding planted acreage and increasing weed, disease and insect pressure.
Part of Corteva’s price decline is company-specific. Certain pre-emergence herbicides recently lost patent protection, requiring Corteva to compete against generic alternatives. Management said it prepared by lowering the products’ cost structure, enabling the company to retain share and margins despite reducing prices.
Corteva does not expect prices to recover in Brazil during 2026. However, management described the distribution channel as healthy and appropriately stocked rather than excessively burdened with inventory. Strong expected product use should allow Corteva to generate solid volumes even without a pricing rebound.
The strategic response will be to replace maturing products with patented technologies that can command premiums. Haviza, a fungicide expected to launch first in Brazil within the next several years, is the next major product in that cycle.
Crop Protection Pipeline and New Corteva Strategy — Answered by Luther Kissam
Kissam, who is expected to lead New Corteva after the separation, identified the company’s employees, differentiated portfolio and research pipeline as its principal strengths.
Approximately two-thirds of the current crop protection portfolio consists of differentiated technology. The company is not heavily dependent on a single active ingredient, crop, product category or geographic market. Kissam also highlighted Corteva’s ability to combine synthetic chemistry with biological products, allowing the company to offer integrated solutions rather than treating biologicals as a stand-alone category.
The research pipeline includes seven new active ingredients expected to reach the market during the next decade. Kissam characterized it as the strongest crop protection pipeline in the industry and said the company’s greenhouse research demonstrated effective results against targeted weeds and diseases.
The pipeline will be critical to New Corteva’s investment narrative. Established products inevitably lose exclusivity and experience lower prices. New actives, biological products and seed treatments will need to replace that value and sustain margins. Corteva’s strategy is therefore based on continually shifting the portfolio toward differentiated products while lowering the cost base of products approaching patent expiration.
2027 Earnings Target and Longer-Term Framework — Answered by Luther Kissam, Charles Magro and David Johnson
Management remains comfortable with the previously established target of approximately $4.4 billion in combined-company EBITDA for 2027. Corteva’s updated 2026 midpoint of $4.2 billion leaves a relatively modest increase required to reach that goal.
Johnson noted that the original improvement plan was expected to be front-loaded because cost savings and productivity gains would materialize earlier in the cycle. Licensing income has progressed more quickly than anticipated, which could provide additional support in 2027. Management also said separation-related dissynergies should not prevent the businesses from meeting the target.
At the Sept. 15 investor events, New Corteva and Vylor are expected to provide separate financial frameworks extending through 2029. Those presentations will be important because the $4.4 billion target applies to the combined company, while investors will soon need to evaluate two independent earnings profiles.
Separation, Vylor and New Corteva — Answered by Charles Magro, David Johnson and Kimberly Booth
Corteva continues to target Oct. 1 for the separation. Vylor will become the independent advanced seed and genetics company, while the remaining Corteva business will focus on crop protection.
Management has publicly filed the Form 10 registration statement, named the leadership teams, appointed the boards of directors and begun discussions with credit-rating agencies regarding the capital structures. Remaining steps include amendments to the Form 10, completion of information-technology work, final capital structures and regulatory effectiveness of the filing.
The most encouraging separation development is the reduction in expected dissynergies. Corteva originally estimated approximately $100 million in annual dissynergies, but management now expects only about a $25 million headwind in 2026 related primarily to the timing of separation work. On a continuing run-rate basis, Corteva said most of the impact has already been offset.
Johnson argued that this provides an early demonstration of what the two independent companies may be able to accomplish. Separate management structures should allow each business to pursue more focused productivity programs, investment priorities and capital-allocation policies.
Both companies will hold investor events Sept. 15 at the New York Stock Exchange. Management plans to provide additional information on strategy, research pipelines, financial targets and capital allocation.
Second-Half Earnings Timing and Risks — Answered by Charles Magro
Corteva expects second-half EBITDA of approximately $500 million, roughly unchanged from 2025. That follows a particularly strong second half last year, when EBITDA increased 16% from 2024.
The earnings will be heavily concentrated in the fourth quarter. Management expects the third quarter to produce an operating EBITDA loss of approximately $100 million, with fourth-quarter seed shipments and other seasonal activity generating the full second-half profit.
Second-half headwinds include lower crop protection prices, the remaining $25 million in separation dissynergies, increased logistics and freight expenses, tariffs and costs related to the Middle East conflict. Corteva expects higher volumes in both Seed and Crop Protection, along with slightly favorable currency movements, to offset much of those pressures.
The fourth-quarter concentration adds execution risk because delayed Brazilian orders, planting disruptions or unexpected cost increases would affect a relatively narrow earnings window. However, management said the second-half share of annual EBITDA remains generally consistent with the company’s historical seasonality.
Productivity and Margin Expansion — Answered by Charles Magro and David Johnson
Corteva’s previous three-year plan called for approximately $1 billion in gross cost and productivity benefits and about $700 million in net benefits. Some of those gains came from lower commodity and raw-material expenses and may not repeat during the next planning cycle.
Even so, management sees additional opportunities in manufacturing, organizational design, asset utilization and procurement. Crop Protection has already announced restructuring and manufacturing-footprint actions, while the separation should allow each company to manage its cost structure around its specific business model.
For Vylor, productivity opportunities will center on seed production, logistics, research investment and licensing. New Corteva will have a different set of opportunities involving manufacturing plants, active-ingredient sourcing and portfolio simplification. The two companies will disclose more detailed productivity plans in September.
Free Cash Flow — Answered by Charles Magro
Corteva expects normalized free cash flow to remain within its long-term target of approximately 45% to 50% of EBITDA. Management estimated that 2026 conversion would have been around 46% without several unusual cash requirements.
Reported first-half operating cash flow was reduced by a $1.1 billion pension contribution, the Bayer agreement, restructuring expenses and separation-related costs. Those items make the current-year cash-flow results less representative of the underlying earnings capacity of the businesses.
The normalized conversion target suggests that a combined business producing $4.2 billion in EBITDA would ordinarily generate substantial cash for investment, debt management and shareholder returns. The separate capital-allocation priorities of Vylor and New Corteva will be disclosed at the investor events.
Agricultural Outlook and Principal Risks — Answered by Charles Magro
Management believes the agricultural backdrop remains broadly consistent with the assumptions behind Corteva’s earlier strategic plan. Global demand for grains and oilseeds remains strong, and crop prices are modestly higher than a year earlier. Internal performance in licensing, new-product adoption and cost management is running somewhat ahead of the original plan.
The principal weakness is farmer profitability. Brazilian producers face high interest rates, currency uncertainty, limited credit and expensive fuel and fertilizer. Crop protection pricing remains competitive, and dry weather in parts of Europe and the U.S. may reduce fungicide applications.
Corteva also identified tariffs, foreign-exchange movements, geopolitical instability and the Middle East conflict as potential second-half risks. These issues could increase freight, manufacturing and input costs even when underlying seed and crop protection demand remains intact.
Overall Assessment
Corteva’s results show a company approaching its separation with solid operating momentum. Seed demand is benefiting from premium genetics, modest U.S. corn share gains and faster-than-planned licensing growth. Crop Protection is producing volume growth and maintaining margins despite price pressure because Corteva reduced costs ahead of patent expirations and is shifting revenue toward newer products.
The central question is whether those advantages can continue once the businesses operate independently. Vylor will inherit the more seasonally concentrated but technology-driven seed business. New Corteva will inherit a more geographically and product-diverse crop protection operation, but one that must continually replace mature products with patented chemistry and biological innovations.
Near-term risks are concentrated in Brazil, where farmer credit and input expenses could delay seed orders, and in crop protection, where no pricing recovery is expected during 2026. Nevertheless, Corteva’s higher guidance, reduced separation costs and confidence in the $4.4 billion 2027 EBITDA framework indicate management believes the two businesses will begin independent operations from positions of financial and competitive strength.
Source: Corteva second-quarter 2026 earnings call and management commentary.
AG POLICY & MARKETS DAILY | EARNINGS ANALYSIS | CORTEVA — FRIDAY, JULY 31, 2026
